SCHEMBL5756087

SCHEMBL5756087

FC(F)(F)c1cccc(-c2cn(Cc3ccc(Cl)c(C(F)(F)F)c3)cn2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.47
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HPGDS O60760 1/20 0.43
GRIN2B Q13224 1/20 0.42
GPR55 Q9Y2T6 1/20 0.42
CYP2E1 P05181 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2A6 P11509 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2B6 P20813 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDR P35968 1/20 0.41
TEK Q02763 1/20 0.41
KCNN4 O15554 3/20 0.41
PHF8 Q9UPP1 1/20 0.41
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5758123 0.84 KDM5B (0.50) KDM4CMEN1KMT2AHPGDSGRIN2B
SCHEMBL5758218 0.82 KDM5B (0.48) KDM4CCYP3A4CYP2C9CYP2C19KCNN4
SCHEMBL5758287 0.80 GRIN2B (0.41) KDM4CGRIN2BKCNN4PHF8
SCHEMBL5756587 0.78 NPC1 (0.48) KDM4CHPGDSCYP2E1CYP3A4CYP2D6
SCHEMBL5757747 0.77 PHF8 (0.51) KDM4CHPGDSCYP2E1CYP3A4CYP2D6
SCHEMBL5754960 0.76 P2RX7 (0.42) KDM4CGRIN2BKDRPHF8
SCHEMBL5758470 0.73 NPC1 (0.53) KDM4CHPGDSCYP2E1CYP3A4CYP2D6
SCHEMBL5759382 0.72 HPGDS (0.59) KDM4CHPGDSCYP2E1CYP3A4CYP2D6
SCHEMBL5410313 0.71 HPGDS (0.55) KDM4CHPGDSCYP2E1CYP3A4CYP2D6
SCHEMBL5755514 0.71 NPC1 (0.60) KDM4CHPGDSCYP2E1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1194144-B1 ANTIBACTERIAL COMPOUNDS AFFINIUM PHARM INC (CA) 2006-11-02 EP claimed
US-20030149089-A1 Antibacterial compounds SMITHKLINE BEECHAM CORPORATION 2003-08-07 US claimed
JP-2003500357-A 2003-01-07 JP claimed
EP-1194144-A4 ANTIBACTERIAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2002-08-07 EP claimed
EP-1194144-A1 ANTIBACTERIAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-10 EP claimed
WO-2000071120-A1 ANTIBACTERIAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2000-11-30 WO claimed
EP-1194144-B1 ANTIBACTERIAL COMPOUNDS AFFINIUM PHARM INC (CA) 2006-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149089-A1 Antibacterial compounds MRPL21, MRPS28, SPOUT1 KDM4C 4439/4885MEN1 1673/4885KMT2A 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.